Perspective Therapeutics, Inc.

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
10.75 ^USD	+2.48%		+8.92%	+167.41%

Jul. 01	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Comp Value Index	CI
Jul. 01	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Completeness Index	CI

Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Completeness Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2000 Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000E Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000 Growth Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2500 Value Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000 Value Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2000 Value Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000E Growth Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2000 Growth Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2000 Dynamic Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2500 Growth Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 2500 Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000 Index	Jun. 30	CI
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to Russell 3000E Value Index	Jun. 30	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 12	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Jun. 12	MT
Perspective Therapeutics to Join Russell 3000 Index on July 1	Jun. 12	MT
Perspective Therapeutics to Reverse Split Common Shares	Jun. 11	MT
Perspective Therapeutics Prices $80 Million Share, Warrant Offering	May. 24	MT
Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	May. 15
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	May. 15	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target	May. 14	MT

Chart Perspective Therapeutics, Inc.

Duration

Period

More charts

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-Î±-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Perspective Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.75 USD

Average target price

22.25 USD

Spread / Average Target

+106.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PERSPECTIVE THERAPEUTICS, INC.	+167.41%	725M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+41.02%	39.84B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.02B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research